Activest Wealth Management Increases Position in Novo Nordisk A/S $NVO

Activest Wealth Management lifted its stake in Novo Nordisk A/S (NYSE:NVO) by 40.6% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 15,142 shares of the company’s stock after buying an additional 4,376 shares during the period. Activest Wealth Management’s holdings in Novo Nordisk A/S were worth $1,051,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of the stock. BIP Wealth LLC grew its position in shares of Novo Nordisk A/S by 3.9% in the 4th quarter. BIP Wealth LLC now owns 3,642 shares of the company’s stock valued at $313,000 after buying an additional 138 shares during the last quarter. Xponance Inc. grew its position in shares of Novo Nordisk A/S by 5.0% in the 1st quarter. Xponance Inc. now owns 3,314 shares of the company’s stock valued at $230,000 after buying an additional 158 shares during the last quarter. Foster Dykema Cabot & Partners LLC grew its position in shares of Novo Nordisk A/S by 3.8% in the 1st quarter. Foster Dykema Cabot & Partners LLC now owns 4,526 shares of the company’s stock valued at $319,000 after buying an additional 166 shares during the last quarter. 180 Wealth Advisors LLC grew its position in shares of Novo Nordisk A/S by 3.6% in the 1st quarter. 180 Wealth Advisors LLC now owns 5,014 shares of the company’s stock valued at $348,000 after buying an additional 173 shares during the last quarter. Finally, LRI Investments LLC grew its position in shares of Novo Nordisk A/S by 1.4% in the 4th quarter. LRI Investments LLC now owns 13,060 shares of the company’s stock valued at $1,123,000 after buying an additional 176 shares during the last quarter. 11.54% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research firms recently commented on NVO. Wall Street Zen downgraded shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Saturday, August 2nd. BNP Paribas raised shares of Novo Nordisk A/S from an “underperform” rating to a “neutral” rating in a research report on Wednesday, August 13th. Zacks Research downgraded shares of Novo Nordisk A/S from a “hold” rating to a “strong sell” rating in a research report on Wednesday, August 20th. Hsbc Global Res downgraded shares of Novo Nordisk A/S from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 31st. Finally, UBS Group downgraded shares of Novo Nordisk A/S from a “buy” rating to a “neutral” rating in a research report on Tuesday, August 5th. Three research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Novo Nordisk A/S presently has an average rating of “Hold” and a consensus target price of $81.00.

Novo Nordisk A/S Trading Up 0.7%

Shares of Novo Nordisk A/S stock opened at $56.51 on Friday. Novo Nordisk A/S has a 1 year low of $45.05 and a 1 year high of $139.74. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.56 and a current ratio of 0.78. The company has a market capitalization of $252.29 billion, a P/E ratio of 15.52, a PEG ratio of 1.95 and a beta of 0.63. The company’s fifty day moving average is $60.72 and its two-hundred day moving average is $68.44.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings data on Wednesday, August 6th. The company reported $0.97 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.93 by $0.04. Novo Nordisk A/S had a net margin of 35.60% and a return on equity of 78.64%. The company had revenue of $11.69 billion for the quarter, compared to the consensus estimate of $77.51 billion. Analysts forecast that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Cuts Dividend

The company also recently announced a semi-annual dividend, which was paid on Tuesday, August 26th. Stockholders of record on Monday, August 18th were paid a $0.4119 dividend. This represents a dividend yield of 240.0%. The ex-dividend date was Monday, August 18th. Novo Nordisk A/S’s dividend payout ratio (DPR) is 22.53%.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.